Episode Notes
Resources:
Today, Jason Shuris, Chief Business Officer of Indero, formerly known as Innovaderm, is here to discuss an exciting transition for the CRO. Welcome back to Phase Forward! The team is thrilled to have a returning guest who brings extensive healthcare and life science expertise to the discussion. For listeners who might not yet have heard the news, Innovaderm is officially rebranding to the name Indero as of March 7th, 2025.
The Why
The transition, which coincides with the company’s 25th anniversary, was driven by the expansion into rheumatology services alongside dermatology. This expansion necessitated rebranding the company, as the market could no longer be approached under the Innovaderm name. After an extensive evaluation of various names, trademarks, and competitive landscapes, the name Indero was chosen. Over the past 12 months, preparations for this rebranding and launch have been underway.
Approach
A comprehensive rebranding strategy was developed, involving various internal and external stakeholders. The transition from Innovaderm to Indero aims to reposition the company in the marketplace without any changes in ownership or mergers. The expansion into a different therapeutic area necessitated the rebranding to ensure market clarity about the company’s identity and services. Maintaining excellence in scientific rigor and quality remains a priority.
Innovaderm’s reputation for understanding the nuances of running dermatology trials is being leveraged in the rheumatology sphere. No other rheumatology focused CROs were found, highlighting an unmet need in the market. The goal is to fill this gap by offering rigorous and expert services in both dermatology and rheumatology.
Potential Risks and Benefits Associated with the Transition
The primary risk involves avoiding confusion in the market. Innovaderm has built a strong 25-year reputation, and it is crucial to ensure that the transition to Indero is clearly understood. The core values of providing dermatology and rheumatology services remain unchanged. Communicating this transition effectively to the markets is vital to maintain brand loyalty and recognition.
The benefits include a stronger brand identity in both dermatology and rheumatology. Being the first CRO to market in the rheumatology specific sphere is significant. The rebranding allows the attraction of new clients, particularly those focused solely on rheumatology.
Leveraging global capabilities is also important, as the company has expanded into Europe, Latin America, and Asia Pacific. The rebranding provides an opportunity to introduce the Indero brand globally.
The Vision of Indero
Maintaining the company’s identity and core values is essential. The commitment to scientific excellence and high-quality service must remain intact. Understanding the clinical trial landscape and investigator landscape is key. The approach used in dermatology is being applied to rheumatology, offering a tailored expert approach to both therapeutic areas. We are now a dual-focused CRO, filling a market gap and offering a tailored expert approach to both therapeutic areas. The potential for rapid growth and an expanding reputation in rheumatology is significant. The hard work and effort put into this transition are expected to yield great results, benefiting many companies that previously lacked access to these services.
As we conclude another illuminating episode of Phase Forward, we find ourselves at the crossroads of science and progress. Remember that behind the jargon and statistics, lies stories of unwavering commitment, meticulous observation, and the pursuit of evidence that shapes our understanding of health and disease. Stay at the forefront of knowledge and innovation and follow Phase Forward on your preferred platform. My name is Valerie Coveney. Thank you for joining us. Until next time.
Let’s shape the future of research and make a difference in the industry, gain Indero’s support in your upcoming trial and propel your study to new heights.
